SCHEMBL1647496

SCHEMBL1647496

O=[N+]([O-])c1ccc(-c2cocn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
MAPT P10636 9/20 0.46
LMNA P02545 3/20 0.46
NOTUM Q6P988 1/20 0.45
APP P05067 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
POLB P06746 2/20 0.41
PKM P14618 1/20 0.41
MCL1 Q07820 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646144 0.94 ALDH1A1 (0.50) RAB9ANPC1MAPTLMNAAPP
SCHEMBL7256592 0.81 RAB9A (0.55) RAB9ANPC1MAPTLMNAALDH1A1
SCHEMBL30461131 0.75 RAB9A (0.64) RAB9ANPC1MAPTLMNAAPP
SCHEMBL4089020 0.74 MAPT (0.54) MAPTALDH1A1KMT2AMEN1TDP1
SCHEMBL21952859 0.73 SCN9A (0.38) RAB9ANPC1MAPTALDH1A1CYP3A4
SCHEMBL30461132 0.72 MAOB (0.54) RAB9ANPC1MAPTLMNAAPP
SCHEMBL27617094 0.72 RAB9A (0.56) RAB9ANPC1MAPTLMNAAPP
SCHEMBL9316416 0.71 MAPT (0.45) RAB9ANPC1MAPTLMNANOTUM
SCHEMBL12878846 0.71 PTGS2 (0.45)
SCHEMBL5999068 0.71 HDAC4 (0.44) RAB9ANPC1MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101041643-A Synthesis of 4-(4- nitrobenzene radical) oxazole XUZHOU RUISAI TECHNOLOGY INDUS (CN) 2007-09-26 CN claimed
US-20250066364-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2025-02-27 US disclosed
EP-4406616-A2 SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2024-07-31 EP disclosed
US-11932645-B2 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders Bial—R & D Investments, S.A. (PT) 2024-03-19 US disclosed
EP-3215510-B1 SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2023-06-07 EP disclosed
US-11400095-B2 Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2022-08-02 US disclosed
US-11351173-B2 Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2022-06-07 US disclosed
US-20220169652-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2022-06-02 US disclosed
US-11091492-B2 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2021-08-17 US disclosed
US-11091492-B2 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2021-08-17 US disclosed
EP-1857108-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE Astellas Pharma Inc. (JP) 2007-11-21 EP disclosed
EP-1844776-A1 AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS Astellas Pharma Inc. (JP) 2007-10-17 EP disclosed
EP-1844775-A1 THERAPEUTIC AGENT FOR HERPES PROGENITALIS Astellas Pharma Inc. (JP) 2007-10-17 EP disclosed
CN-101041643-A Synthesis of 4-(4- nitrobenzene radical) oxazole XUZHOU RUISAI TECHNOLOGY INDUS (CN) 2007-09-26 CN disclosed
CN-101041643-A Synthesis of 4-(4- nitrobenzene radical) oxazole XUZHOU RUISAI TECHNOLOGY INDUS (CN) 2007-09-26 CN disclosed
US-20060229295-A1 Amide derivatives ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) 2006-10-12 US disclosed
EP-1652843-A1 AMIDE DERIVATIVES Astellas Pharma Inc. (JP) 2006-05-03 EP disclosed
US-6903125-B2 Tetrahydro-2H-thiopyran-4-carboxamide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-06-07 US disclosed
US-20050032855-A1 Tetrahydro-2H-thiopyran-4-carboxamide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. 2005-02-10 US disclosed
WO-2003040141-A1 OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11351173-B2 Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders TYMP, PARK7, PNP RAB9A 1802/4885NPC1 1314/4885MAPT 82/4885
US-11932645-B2 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders PARK7, PNP, GAA RAB9A 1498/4885NPC1 706/4885MAPT 62/4885
US-20050032855-A1 Tetrahydro-2H-thiopyran-4-carboxamide derivative TPMT, RPL35, TYMP RAB9A 1379/4885NPC1 3767/4885MAPT 1656/4885
US-11400095-B2 Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders GBA1, GAA, SNCA RAB9A 1316/4885NPC1 697/4885MAPT 80/4885
US-20220169652-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS PARK7, PNP, GAA RAB9A 1498/4885NPC1 706/4885MAPT 62/4885
US-20250066364-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS PARK7, PNP, GAA RAB9A 1498/4885NPC1 706/4885MAPT 62/4885
US-20060229295-A1 Amide derivatives VAC14, HDAC8, ZC3HAV1 RAB9A 741/4885NPC1 3393/4885MAPT 2138/4885
US-11091492-B2 Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders PARK7, PNP, GAA RAB9A 1498/4885NPC1 706/4885MAPT 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.